How many GP visits should a patient have in the first year after a heart attack?

The Australian study does not specify an optimal visit number, but found a clear dose-response relationship — greater visit frequency was associated with progressively lower risks of rehospitalisation and death. Current Australian and international cardiac guidelines recommend structured follow-up at one month, three months, and six months post-discharge, with additional visits based on symptom burden and medication adjustment. Patients with comorbidities (heart failure, chronic kidney disease, diabetes) warrant more frequent contact.

What are the four guideline-recommended medicines after a heart attack?

For most patients following an acute coronary syndrome, current Australian guidelines (consistent with Heart Foundation guidance and eTG Cardiovascular) recommend: an antiplatelet agent (aspirin, with dual antiplatelet therapy for 12 months following stent placement), a beta-blocker, an ACE inhibitor or ARB, and a high-intensity statin. Individual contraindications apply. Only 75% of patients in this study received at least one of these medicines, and fewer than 20% received all four — indicating a significant quality-of-care gap in cardiac secondary prevention.

More GP visits after a heart attack cuts death risk by 13%

Most people think the most dangerous part of a heart attack is the event itself.

The Australian data says something different. A 10-year study of linked health records from over 2,000 patients who survived a coronary event found that what happens in general practice in the first year after discharge is associated with survival in a way that is clinically meaningful and largely within our reach to change.

Researcher Sangita Shakya put it directly: “Recovery from a heart attack doesn’t stop when you leave the hospital. In fact, that is when the most important stage of your recovery begins.”

The data agrees.

What the study found

The research, published in the European Journal of Cardiovascular Nursing in 2026, analysed 10 years of linked health data (2010–2022) from patients with both coronary heart disease and type-2 diabetes in Western Australia. The combined comorbidity profile — heart disease plus diabetes — is a high-risk population, and also a common one in Australian general practice.

Greater GP visit frequency in the 12 months following a coronary event was associated with a 6% reduction in recurrent rehospitalisation and a 13% lower risk of death. These are meaningful numbers at a population level and they reflect something intuitive: patients who see their GP regularly after a cardiac event are having their medications reviewed, their risk factors managed, and their symptoms assessed early.

The medication finding is the part worth pausing on. Only 75% of patients in the cohort received at least one of the four guideline-recommended medicines for secondary cardiac prevention. Fewer than one in five received all four. This is not a guideline-knowledge problem. It is a care-coordination and follow-up problem — the kind that accumulates in the gap between hospital discharge and the first GP visit.

The geography finding

The geographic disparities in this study are stark and directly relevant to how Australian general practice is resourced.

People in outer regional areas faced a 31–35% higher risk of recurrent rehospitalisation compared with patients in major cities. For patients in remote areas, the mortality risk was 57–68% higher.

These disparities reflect unequal access to cardiac rehabilitation services, specialist follow-up, and timely GP visits. They are not explained by differences in disease severity alone. They reflect what happens when the infrastructure of follow-up care is thinner.

For GPs working in regional or rural settings, this data confirms what they already know from practice: their role in the post-cardiac follow-up is not supplementary to specialist care — it is often the primary source of structured follow-up available to their patients.

Both sides of this

The case for more structured GP follow-up after cardiac events is now backed by Australian linked data, not just inference. That is useful — it gives practitioners evidence to take into conversations about resource allocation, care planning, and billing structures.

The complication: general practice is already under pressure. Adding more structured follow-up in the post-cardiac population requires time, recall systems, care plan infrastructure, and coordination between hospitals and general practice that does not always exist. The data shows what better follow-up is associated with; it does not solve the system-level obstacles to achieving it. That gap between what works and what the system can deliver is a legitimate policy problem, and this study is useful evidence in that policy argument.

The other side of the medication finding is worth naming. Fewer than one in five patients on all four guideline medicines is a number that reflects both the post-discharge medication gap and the clinical reality that some patients have contraindications, tolerability issues, or preferences that limit the full regimen. Guideline adherence in this population is a process indicator, not a direct quality measure for individual GPs. Context matters. But where all four medicines are appropriate and not prescribed, that gap is worth closing.

What this means in general practice this week

Schedule the follow-up before the patient leaves hospital — or within days of their return home. The post-discharge gap is where the risk accumulates. A GP visit at two to four weeks post-discharge lets you complete the medication reconciliation, address new symptoms, and establish the follow-up rhythm for the year ahead. For patients seen via a shared care arrangement, make sure someone owns the first post-discharge visit — and that it is not assumed to be happening when it may not be.

Run through all four guideline medicines at the post-cardiac review. The study’s medication finding — fewer than one in five patients on all four recommended medicines — identifies a quality-of-care gap that a structured consultation can address. Antiplatelet therapy, beta-blocker, ACE inhibitor or ARB, high-intensity statin: document why each is present, absent, or modified. Where contraindications exist, document them. Where a medicine was not initiated at discharge, consider whether to start it.

Flag regional and remote patients for closer follow-up. The geographic mortality data is a prompt. Patients who are geographically distant from cardiac rehabilitation, specialist follow-up, and even consistent GP access need their follow-up calendar structured more deliberately, not left to patient-initiated contact.

Use the care plan framework. A GP management plan with scheduled care plan reviews provides the billing and documentation structure that supports coordinated follow-up in the cardiac patient population. For patients with both coronary heart disease and diabetes — the cohort in this study — a team care arrangement involving cardiac rehabilitation, dietetics, and diabetes education is appropriate and supported by MBS item numbers.

Heart attack survival has improved substantially over three decades. The research signals that survival is only the beginning. What happens in general practice in the year that follows is where the difference is made.

Verdict: yes — structured GP follow-up in the first year after a heart attack saves lives. The evidence is now Australian.